Printer Friendly

BARR AND FDA RESUME NEGOTIATIONS

 BARR AND FDA RESUME NEGOTIATIONS
 POMONA, N.Y., Aug. 24 /PRNewswire/ -- On Wednesday, Aug. 19, Barr


Laboratories, Inc. (AMEX: BRL) and the FDA agreed to suspend temporarily further hearings in Federal District Court in Newark which began two days earlier. Both parties agreed to negotiate their differences in an attempt to resolve the dispute without further hearings. The judge, however, made it clear that if talks were to break down, both parties would return to court and the hearings would resume. Negotiations are ongoing.
 In its opening statement on Aug. 17, FDA informed the court it was no longer seeking a total shutdown of Barr Laboratories but rather asking the court to review issues associated with specific products. As yet, there have been no formal rulings in the case.
 -0- 8/24/92
 /CONTACT: Harold Cohen of Barr Laboratories, Inc., 914-362-2823/
 (BRL) CO: Barr Laboratories, Inc. ST: New York IN: MTC SU:


DC-KW -- NY052 -- 2616 08/24/92 13:26 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 24, 1992
Words:161
Previous Article:VITALINK ANNOUNCES ACQUISITION OF NORTHERN NURSING HOME PHARMACY
Next Article:IXSYS INC. GRANTED WORLDWIDE EXCLUSIVE LICENSE BY THE UNIVERSITY OF CALIFORNIA
Topics:


Related Articles
BARR RESPONDS TO FDA LAWSUIT
BARR LABORATORIES PRESENTS ORAL ARGUMENTS BEFORE JUDGE REGARDING TRANSFER MOTION OF FDA ACTION
FDA'S SUIT AGAINST BARR LABORATORIES TRANSFERRED TO NEWARK
BARR LABORATORIES AND FDA MEET WITH DISTRICT COURT JUDGE WOLIN
BARR AND FDA MEET WITH DISTRICT COURT JUDGE WOLIN
BARR AND FDA RESUME COURT HEARINGS
BARR NAMES NEW PRESIDENT AND CHIEF OPERATING OFFICER
BARR REINTRODUCES TWO ADDITIONAL PRODUCTS
BARR LABORATORIES, FDA SETTLE 1992 COURT CASE; COURT'S ORDER ESTABLISHES PROCESS FOR COMPANY TO REINTRODUCE FORMER PRODUCTS
FDA APPROVES BARR'S CIPROFLOXACIN ANTI-BACTERIAL PRODUCT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters